Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ex scientia Ltd
ex scientia Ltd
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Transatlantic partnership to screen 15,000 drugs for COVID-19 treatments
Exscientia has announced a joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research
Research & Development
Exscientia initiates sixth AI drug discovery partnership
Exscientia to receive up to CHF67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche
Analysis
Exscientia appoints Georgy Egorov as Chief Financial Officer
Research & Development
Elsevier welcomes six biotech and pharma start-ups to The Hive
Start-ups working on a range of technologies and discoveries — from AI to immunotherapy — receive complimentary access to Elsevier's information solutions to accelerate innovation
Recruitment
Exscientia appoints Alex Snow as Deputy Chairman
Digital
Exscientia enters drug discovery collaboration with GSK
Exscientia, an innovative artificial intelligence driven drug discovery company, has entered into a strategic drug discovery collaboration with GlaxoSmithKline
Research & Development
Collaboration in bispecific-small-molecule drugs for metabolic disease
€250m agreement between Exscientia and Sanofi is for multiple-product development and licence option
Subscribe now